GICS Sector : Healthcare
SpringWorks Therapeutics, Inc.acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer.Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Oct -21
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Oct -21
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
Aug -18
Immunome: SpringWorks Buyout Informs The Potential Upside Here
Aug -12
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Jul -18
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
Jul -01
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Jun -20
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
May -26
SpringWorks Therapeutics' life-changing medicines drive 10.47% growth, fueled by increasing demand for rare disease treatments, strategic partnerships, and a strong pipeline of novel therapies. Additionally, advancements in gene therapy and precision medicine contribute to the company's rapid expansion.
A monoclonal antibody targeting GD2 for the treatment of neuroblastoma and osteosarcoma
A monoclonal antibody targeting HER2 for the treatment of breast cancer
A small molecule inhibitor of the B-cell lymphoma 2 (BCL-2) protein for the treatment of hematological malignancies
A small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway for the treatment of solid tumors
SpringWorks Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for rare diseases and cancer.
The bargaining power of customers is low due to the specialized nature of SpringWorks Therapeutics, Inc.'s products and the lack of alternative options for patients.
The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's dependence on a few key suppliers.
The threat of new entrants is high due to the growing interest in rare disease and cancer treatment, and the potential for new companies to enter the market.
The intensity of rivalry is high due to the presence of established companies and the increasing competition for market share in the rare disease and cancer treatment market.
| Value | |
|---|---|
| Debt Weight | 1.11% |
| Debt Cost | 3.95% |
| Equity Weight | 98.89% |
| Equity Cost | 8.11% |
| WACC | 8.07% |
| Leverage | 1.13% |
Value: 6.2
Growth: 4.4
Quality: 5.0
Yield: 0.0
Momentum: 9.5
Volatility: 5.3
1-Year Total Return ->
Value: 6.7
Growth: 4.1
Quality: 7.2
Yield: 0.0
Momentum: 4.0
Volatility: 4.3
1-Year Total Return ->
Value: 8.0
Growth: 0.4
Quality: 4.9
Yield: 0.0
Momentum: 6.0
Volatility: 1.7
1-Year Total Return ->
Value: 6.4
Growth: 7.9
Quality: 4.2
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 6.2
Growth: 2.7
Quality: 5.1
Yield: 0.0
Momentum: 4.0
Volatility: 1.0
1-Year Total Return ->
Value: 6.4
Growth: 1.1
Quality: 3.9
Yield: 0.0
Momentum: 1.0
Volatility: 2.7
1-Year Total Return ->